Anillin expression is a marker of favourable prognosis in patients with renal cell carcinoma

Oncology Reports

Volumn 25, Issue 1, 2011, Pages 129-133

  Ronkainen, Hanna ^a   Hirvikoski, Pasi ^a   Kauppila, Saila ^a   Vaarala, Markku H ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Immunohistochemistry; Prognostic marker; Protein expression; Survival

Indexed keywords

ANILLIN; BIOLOGICAL MARKER; CELL MEMBRANE MARKER; KI 67 ANTIGEN; NUCLEAR PROTEIN; PARAFFIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CELL FRACTIONATION; CELL MEMBRANE; CELL NUCLEUS; CELL PROLIFERATION; CLINICAL FEATURE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CONTRACTILE PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650725395     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00001051     Document Type: Article

References (27)

1. Pantuck AJ, Zisman A and Belldegrun AS: The changing natural history of renal cell carcinoma. J Urol 166: 1611-1623, 2001.
2. Breda A, Konijeti R and Lam JS: Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection. Expert Rev Anticancer Ther 7: 847-862, 2007.
3. Bui MH, Zisman A, Pantuck AJ, Han KR, Wieder J and Belldegrun AS: Prognostic factors and molecular markers for renal cell carcinoma. Expert Rev Anticancer Ther 1: 565-575, 2001.
4. Cheville JC, Lohse CM, Zincke H, Weaver AL and Blute ML: Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27: 612-624, 2003. (Pubitemid 36514472)
5. Lang H, Lindner V, Letourneux H, Martin M, Saussine C and Jacqmin D: Prognostic value of microscopic venous invasion in renal cell carcinoma: long-term follow-up. Eur Urol 46: 331-335, 2004.
6. Field CM and Alberts BM: Anillin, a contractile ring protein that cycles from the nucleus to the cell cortex. J Cell Biol 131: 165-178, 1995.
7. Straight AF, Field CM and Mitchison TJ: Anillin binds nonmuscle myosin II and regulates the contractile ring. Mol Biol Cell 16: 193-201, 2005.
8. Miller KG, Field CM and Alberts BM: Actin-binding proteins from drosophila embryos: a complex network of interacting proteins detected by F-actin affinity chromatography. J Cell Biol 109: 2963-2975, 1989.
9. Oegema K, Savoian MS, Mitchison TJ and Field CM: Functional analysis of a human homologue of the drosophila actin binding protein anillin suggests a role in cytokinesis. J Cell Biol 150: 539-552, 2000.
10. Kinoshita M, Field CM, Coughlin ML, Straight AF and Mitchison TJ: Self-and actin-templated assembly of mammalian septins. Dev Cell 3: 791-802, 2002.
11. Hall PA, Todd CB, Hyland PL, McDade SS, Grabsch H, Dattani M, Hillan KJ and Russell SE: The septin-binding protein anillin is overexpressed in diverse human tumors. Clin Cancer Res 11: 6780-6786, 2005.
12. Iatropoulos MJ and Williams GM: Proliferation markers. Exp Toxicol Pathol 48: 175-181, 1996.
13. Scott RJ, Hall PA, Haldane JS, van Noorden S, Price Y, Lane DP and Wright NA: A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol 165: 173-178, 1991.
14. Ronkainen H, Vaarala MH, Kauppila S, Soini Y, Paavonen TK, Rask J and Hirvikoski P: Increased BTB-kelch type substrate adaptor protein immunoreactivity associates with advanced stage and poor differentiation in renal cell carcinoma. Oncol Rep 21: 1519-1523, 2009.
15. Ronkainen H, Kauppila S, Hirvikoski P and Vaarala MH: Evaluation of myosin VI, E-cadherin and beta-catenin immunostaining in renal cell carcinoma. J Exp Clin Cancer Res 29: 2, 2010.
16. Ronkainen H, Soini Y, Vaarala MH, Kauppila S and Hirvikoski P: Evaluation of neuroendocrine markers in renal cell carcinoma. Diagn Pathol 5: 28, 2010.
17. Sobin LH and Wittekind C (eds): TNM Classification of Malignant Tumours (UICC). (6th edition). Wiley & Sons, New York, 2002
18. Ebele JN, Sauter G, Epstein JI and Sesterhenn IA (eds): Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs (IARC). IARC Press, Lyon, 2004.
19. Gerace L, Blum A and Blobel G: Immunocytochemical localization of the major polypeptides of the nuclear pore complexlamina fraction. interphase and mitotic distribution. J Cell Biol 79: 546-566, 1978.
20. Gerace L and Blobel G: The nuclear envelope lamina is reversibly depolymerized during mitosis. Cell 19: 277-287, 1980.
21. Glass CA, Glass JR, Taniura H, Hasel KW, Blevitt JM and Gerace L: The alpha-helical rod domain of human lamins A and C contains a chromatin binding site. EMBO J 12: 4413-4424, 1993.
22. Olakowski M, Tyszkiewicz T, Jarzab M, Krol R, Oczko-Wojciechowska M, Kowalska M, Kowal M, Gala GM, Kajor M, Lange D, Chmielik E, Gubala E, Lampe P and Jarzab B: NBL1 and anillin (ANLN) genes over-expression in pancreatic carcinoma. Folia Histochem Cytobiol 47: 249-255, 2009.
23. Suzuki C, Daigo Y, Ishikawa N, Kato T, Hayama S, Ito T, Tsuchiya E and Nakamura Y: ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway. Cancer Res 65: 11314-11325, 2005.
24. Glotzer M: The molecular requirements for cytokinesis. Science 307: 1735-1739, 2005.
25. Bui MH, Visapaa H, Seligson D, Kim H, Han KR, Huang Y, Horvath S, Stanbridge EJ, Palotie A, Figlin RA and Belldegrun AS: Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 171: 2461-2466, 2004.
26. Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths DF and Williams GH: Mcm2, geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res 11: 2510-2517, 2005.
27. Pertia A, Nikoleishvili D, Trsintsadze O, Gogokhia N, Managadze L and Chkhotua A: Immunoreactivity of p27(Kip1), cyclin D3, and Ki67 in conventional renal cell carcinoma. Int Urol Nephrol 41: 243-249, 2009.